Improvements are particularly notable in melanoma, especially in the setting of BRAF-V600E and BRAF-V600K mutations (4), which represent 40-50% of metastatic melanoma cases and are amenable to targeted therapies (TT) with BRAF/MEK inhibitors (BRAF/MEKi) (5, 6). The gene discussed is BRAF; the disease is metastatic melanoma.